Telix Pharmaceuticals Limited (ASX:TLX)
Share Pricing & News Healthcare

AUD 7.4

0.04 (0.544%)
(As on 2022-12-01 20:57:33 AEDT)
Previous Close Open Close*
7.36 7.45 7.4
Market Cap Dividend Yield (Annualized)
AUD 2.328B 0.00%

Day Range
7.29L 7.46 H
52 WEEK HIGH LOW
3.55L 8.44 H

Chart Price & Information

Last Trade 7.4
Change% 0.5435
52 W H/L 8.440/3.550
EBITDA -107.448M
NPAT After Abnormal Items -44.887M
Equity 79.016M
ROE% -47.58%
Total Liabilities 78.805M
Total Revenue 18.867M
Cash and Cash Equivalents 77.945M

Stock Information

Share price 7.4
Market Cap 2.328B
Price/Gross Cash Flow -46.50
Dividend Yield Excluding Special 0.00%
Ending Shares 280.405M
52-Week Range 8.440-3.550
Gross DPS (AUD) 0
Gross Dividend Yield (Annualized) 0.00%
Earnings Yield 0.000
Net Tangible Asset (NTA) 0.07
P/E ratio 0.000
Sector P/E --
EPS -17.45
EV/EBITDA --
Net Profit Margin (%) -803.33%
Gross Cash Flows Per Share -0.09
Net Gearing -95.85%
Sales Per Share 0.02
Book Value Per Share 0.28

Similar Companies

Related Articles

About Company

Telix Pharmaceuticals Limited (ASX: TLX) under health care sector is engaged into the commercializing and development of molecularly targeted radiation (MTR) products for the treatment of cancer. It is based out of Flemington road, North Melbourne, Australia. The company’s incorporation year was 2017 and is categorized as a bio-pharmaceutical company. Products such as TLX-250, TLX-591 and TLX-101 are included in company’s MTR range.

Corporate Information


Suite 401, 55 Flemington Road, NORTH MELBOURNE, VIC, AUSTRALIA, 3051

Phone:03 3093 3897

Website:http://www.telixpharma.com

Dividends

Ex-Date Net Dividend Frank Flag Period End Date Type Payable

Event Calendar

Event Type Event Date Event Year
Report (Interim) 2023-08-17 2023
Report (Annual) 2023-02-23 2023
Report (Prelim) 2023-02-23 2023